- Announces strategic alliance with GlaxoSmithKline plc to develop and market select products across emerging markets outside India.
- Receives approval for Three INDs.
- Reorganizes Drug Discovery Operations to merge into Aurigene, a wholly owned independent subsidiary of Dr. Reddy's.
- Acquires BASF’s Pharmaceutical manufacturing contract business and related facility at Shreveport, Louisiana
- Acquires Dowpharma’s small molecule business at its Mirfield and Cambridge facilities, UK.
- Dr. Reddy’s formally announces its US Specialty Business, Promius Pharma, LLC.
- Becomes No.1 pharmaceutical company in India in turnover and profitability.
- Launches Reditux ™ (Rituximab) – the World’s first biosimilar of a monoclonal antibody
- Blaglitazone (DRF 2593) enters Phase III of clinical trials becoming India’s most advanced NCE
- Revenues touch USD 1 Billion in December 2006.
- Dr. Reddy's obtains its second 180-day marketing exclusivity for a generic drug in the US market with the launch of Ondenesetron Hydrochloride Tablets.
- Becomes an Authorized Generic Partner for Merck’s Proscar® & Zocor® in the US market during 180 day exclusivity period.
- Acquires betapharm- the fourth-largest generics company in Germany for a total enterprise value of € 480 million.
- Acquires Roche's API Business at the state-of-the-art manufacturing site in Mexico with a total investment of USD 59 million.
- Announces India's first major co-development and commercialization deal for it's molecule Balaglitazone (DRF 2593), with Rheoscience.
- Announces a unique partnership for the commercialization of ANDAs with ICICI Venture..
- Acquires Trigenesis gives access to drug delivery technology platforms
- Launches Ibuprofen, first generic product to be marketed under the “Dr. Reddy’s” label in the US
- Conducts its first overseas acquisition – BMS Laboratories Limited and Meridian Healthcare in UK
- Becomes the first Asia Pacific pharmaceutical company, outside Japan, to list on the New York Stock Exchange. Listed with the symbol ‘RDY’ on April 11, 2001.
- Out-licenses DRF 4158 to Novartis for up to US $55 million upfront payment
- Launches its first generic product, Ranitidine, in the US market
- Becomes the first Indian pharmaceutical company to obtain an 180-day exclusive marketing rights for a generic drug in the US market with the launch of Fluoxetine 40 mg capsules on August 3, 2001
- Dr. Reddy's Laboratories becomes India's third largest pharmaceutical company with the merger of Cheminor Drugs Limited, a group company
- Reddy US Therapeutics, a wholly-owned subsidiary, is established at Atlanta, US to conduct target based drug discovery
- Acquisition of American Remedies Limited, a pharmaceutical company based in India.
- Licenses anti-diabetic molecule, DRF 2725 (Ragaglitazar), to Novo Nordisk
- Licenses anti-diabetic molecule, DRF 2593 (Balaglitazone), to Novo Nordisk. Becomes the first Indian pharmaceutical company to out-license an original molecule.
- First ANDA filed with the United States Food and Drug Administration for Ranitidine
- Sets up of a Joint Venture in Russia.
- Makes a GDR issue of USD 48 million
- Foundation stone laid for a finished dosages facility to cater to the highly regulated markets such as the US.
- Dr. Reddy's Research Foundation established. The company's drug discovery programme starts.
- First formulation exports to Russia commence
- Dr. Reddy’s, for the first time in India, exports Norfloxacin and Ciprofloxacin to Europe and Far East.
- Acquires Benzex Laboratories Pvt. Limited to expand its Bulk Actives business.
- Obtains its first USFDA approval for Ibuprofen API
- Starts its formulations operations
- Dr. Reddy’s goes public
- Dr. Reddy’s listed on Bombay Stock Exchange (BSE)
- Dr. Reddy’s enters international markets with exports of Methyldopa
- Dr Anji Reddy establishes Dr. Reddy's Laboratories with an initial capital outlay of Rs.25 lakhs
Designed by